MJA
MJA InSight
MJA Careers
Letters

Ensuring safety of the 2011 trivalent influenza vaccine in young children

Christopher C Blyth, Tracy Y Markus, Paul V Effler and Peter C Richmond
Med J Aust 2011; 195 (1): 52.

To the Editor: Young children are at increased risk of severe influenza compared with the general population. Routine vaccination of children using trivalent influenza vaccine (TIV) is recommended in the United States and Canada.

Christopher C Blyth, Associate Professor1,2,3
Tracy Y Markus, Paediatric Registrar3
Paul V Effler, Medical Coordinator4
Peter C Richmond, Associate Professor1,2,3
1 School of Paediatrics and Child Health, University of Western Australia, Perth, WA.
2 Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Perth, WA.
3 Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA.
4 Prevention and Control Program, Communicable Disease Control Directorate, WA Health, Perth, WA.
Article References: 
Reference Text: 
Dixon GA, Moore HC, Kelly H, et al. Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory-confirmed influenza in hospitalised children aged 6–59 months. Influenza Other Respi Viruses 2010; 4: 231-234.
Reference Order: 
1
PubMed ID: 
20629773
Reference Text: 
Department of Health and Ageing, Therapeutic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination: status report as at 2 July 2010 (updated 24 September 2010). Canberra: TGA, 2010. http://www.tga.gov.au/safety/alerts-medicine-seasonal-flu-100702.htm#fullreport (accessed May 2011).
Reference Order: 
2
PubMed ID: 
Reference Text: 
Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011. In press.
Reference Order: 
3
PubMed ID: 
Reference Text: 
Blyth CC, Currie AJ, Wiertsema SP, et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 2011. In press. doi: 10.1016/j.vaccine.2011.05.054.
Reference Order: 
4
PubMed ID: 
Reference Text: 
CSL Biotherapies. Fluvax. Product information, October 2010. http://secure.healthlinks.net.au/content/csl/pi.cfm?product=cspfluva11010 (accessed Apr 2011).
Reference Order: 
5
PubMed ID: 

The full contents of this page are only available to subscribers.